ArticleScientific reports2025
Deciphering the interaction between N-palmitoyl-D-glucosamine and the endocannabinoidome.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dual Role of the Spinal Endocannabinoid System in Response to Noxious Stimuli: Antinociceptive Pathways and Neuropathic Pain Mechanisms.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
N-palmitoyl-D-glucosamine (PGA) belongs to the class of molecules known as Autacoid Local Injury Antagonism (ALIA)-amides, whose parent compound is N-palmitoyl-ethanolamine (PEA) an endocannabinoid-like mediator belonging to the expanded endocannabinoid system (the endocannabinoidome). The mechanism of action of ALIA-amides is mainly targeted at the down-regulation of the hyperactivity of peripheral mast cells and non-neuronal cells of the central nervous system. This study aimed to investigate if PGA is able to produce the typical "entourage" effect of PEA, consisting of increasing the endogenous levels of the endocannabinoids anandamide (AEA) and 2-arachidonoylglycerol (2-AG), and to also elevate endogenous PEA levels. PGA (10 µM) treatment of HaCaT cells for 40 min and 6 h resulted in higher cellular concentrations of AEA, 2-AG and PEA. The increase of endocannabinoid and PEA levels was observed both after 40 min and 6 h of PGA treatment. The unselective serine hydrolase inhibitor MAFP (10 µM) inhibited the PGA-induced increase in cellular concentrations of AEA, 2-AG and PEA. The mRNA expression of endocannabinoid and PEA anabolic (NAPEPLD, ABHD4, GDE1, DAGLA and DAGLB) and catabolic (FAAH, MAGL and NAAA) enzymes was also measured, revealing a significative reduction of GDE1, DAGLB, FAAH, MAGL and NAAA, after PGA treatment for 6 h. Finally, AEA, 2-AG and PEA were also measured in HaCaT cells after siRNA against ABHD4 and PGA treatment for 40 min, revealing an increase of their endogenous levels. In conclusion, we demonstrated for the first time that PGA increases PEA and endocannabinoid levels, thus potentially strengthening a part of endocannabinoidome signaling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.